NCT06915142View on ClinicalTrials.gov

A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour

PHASE2RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

October 31, 2027

Conditions
Advanced Malignant Tumour
Interventions
DRUG

HRS-7058 + SHR-1316

HRS-7058 + SHR-1316

DRUG

HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy

HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy

DRUG

HRS-7058 + Cetuximab

HRS-7058 + Cetuximab

DRUG

HRS-7058 + SHR-1826

HRS-7058 + SHR-1826

DRUG

HRS-7058 + SHR-1826 + SHR-1316

HRS-7058 + SHR-1826 + SHR-1316

Trial Locations (1)

300060

RECRUITING

Tianjin Cancer Hospital, Tianjin

All Listed Sponsors
lead

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY